Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis

Dr Michael Hunter¹, Dr Maurice B. Loughrey², Dr Moyra Gray², Dr Peter Ellis³, Dr Neil McDougall¹, Dr Michael Callender¹

Accepted 5 November 2010

LIST OF ABBREVIATIONS:
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; AMA, anti-mitochondrial antibody; ANA, anti-nuclear antibody; AST, aspartate transaminase; ERCP, endoscopic retrograde cholangiopancreatography; GGT, γ-glutamyl transpeptidase; HAI, hepatic activity index; IAHG, international autoimmune hepatitis group; IgG, Immunoglobulin G; IgM, Immunoglobulin M; LFTs, liver function tests; MRC, magnetic resonance cholangiography; OLS, overlap syndrome; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; SMA, smooth muscle antibody.

ABSTRACT
Aims: Overlap syndromes constitute a significant proportion of autoimmune liver disease. Our aim was to describe our cohort and evaluate practical methods of correctly diagnosing autoimmune hepatitis / primary sclerosing cholangitis overlap syndrome as early as possible clinically.

Methods: 118 autoimmune hepatitis patients were screened for cholestatic liver function tests. 24 patients with cholestatic liver function tests were investigated for possible primary sclerosing cholangitis by clinicopathological review and magnetic resonance cholangiography. Retrospectively, potential predictors of autoimmune hepatitis / primary sclerosing cholangitis overlap syndrome were compared with a control group.

Results: Overlap syndrome was diagnosed in twelve (50%) of 24 autoimmune hepatitis patients with recent cholestasis. The cholestatic group had a lower AST (p=0.012) and International Autoimmune Hepatitis Group (IAHG) score (p=0.102), and higher IgM (p=0.002) at disease presentation. More patients in the cholestatic group developed ulcerative colitis (p=0.138).

Conclusions: Identifying AIH / PSC overlap syndrome at diagnosis is often difficult. Certain clinical and biochemical features should alert the clinician. All patients with AIH, and biochemical cholestasis should be investigated with MRC.

Keywords: Autoimmune hepatitis; overlap; primary sclerosing cholangitis.

INTRODUCTION
Autoimmune liver disease largely comprises autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC). The understanding, definition, and treatment of autoimmune liver disease has changed since first described during the 1950s. Narrower case definitions and improved treatment have resulted from increased clinical awareness, enhanced by biochemical, serological, histological, and radiological techniques¹,².

Since the 1980s, “overlap syndromes” (OLS) of autoimmune liver diseases have been described. OLS indicates a variant form of autoimmune liver disease with characteristics of AIH and PSC or AIH and PBC. The patient may present with features suggesting OLS, or develop them during the course of an initially “pure” autoimmune liver disease. Accurate categorisation and characterisation of overlap syndromes requires a high index of suspicion during evaluation of clinical, biochemical, immunological, histological and radiological features. Patients with OLS have a different disease course and require specific therapy. Compared to 20 years ago, overlap syndromes are more frequently diagnosed ³, and have been the subject of several recent clinical reviews⁴,⁵. Recognising OLS early offers optimum disease management to individual patients. Clearly defining OLS, rather than only utilising pure diagnostic categories of

1: Regional Liver Unit, Royal Victoria Hospital, Belfast
2: Department of Pathology, Royal Victoria Hospital, Belfast
3: Department of Radiology, Royal Victoria Hospital, Belfast
Corresponding Author: Michael Hunter, Department of Infectious Diseases, 3rd Floor, East Wing, Royal Victoria Hospital, Grosvenor Road, BT12 6BA
e-mail: michaelgarvinhunter@hotmail.com
phone: ++44 7964 525278 fax: ++44 2890 634425
autoimmune liver disease, offers an opportunity to assess pathogenic mechanisms and develop treatment strategies.

Fig 1. Time to diagnosis of AIH / PSC ‘overlap’ syndrome in patients with AIH. n=118

A useful tool in the study of autoimmune liver disease has been the International Autoimmune Hepatitis Group (IAHG) ‘score’ for AIH. This scoring for AIH was introduced in 1992 and subsequently revised in 1999. The IAHG score has been validated by prospective review, and found to have high sensitivity (98%) and moderate specificity (60-80%) for a diagnosis of AIH. These IAHG criteria have not been designed or validated for OLS. However the criteria have enabled clinicians to compare cohorts of patients, and objectively study other liver diseases for features of AIH.

In cohorts of patients with AIH, the incidence of AIH / PSC OLS is described between 7% and 10%. In cohorts of patients with PSC, the incidence of AIH / PSC OLS has been described as 7% [12], 8% [13], 17% [14], and 54% [15]. The variation in prevalence rates may be attributed to different patient inclusion criteria and methods of screening for disease. Study analysis reveals that some retrospective studies suffer from incomplete data, poorly defined patient groups, and variation of the criteria used for diagnosis.

The clinical importance of early diagnosis, the improved quality and availability of Magnetic Resonance Cholangiography (MRC), and the variation of disease prevalence between previously published cohorts suggest a need for further investigation. This study seeks to define the epidemiology of AIH / PSC OLS retrospectively in a cohort of patients with AIH, and to determine which investigations should be rationally employed to improve diagnosis.

METHODS

Patient selection

118 patients attending the Liver Clinic in a large, teaching hospital with a diagnosis of autoimmune hepatitis, were included in the study. The initial diagnosis was based on clinical presentation, biochemistry, immunoglobulins and autoantibody profiles and, where a liver biopsy was performed, histology. Follow-up since initial diagnosis ranged from 2 to 26 years [median 12 years].

Table 1: Clinical and laboratory characteristics at clinical presentation of AIH patients who developed cholestatic LFTs and a control AIH group

| Characteristic                  | Cholestatic group (n=24) | Control group (n=26) | p-value  |
|--------------------------------|--------------------------|----------------------|----------|
| Female (%)                     | 14 (58)                  | 15 (60)              | 1.000    |
| Age at presentation (years)    | 40.2 (±15.6)             | 43.4 (±15.7)         | 0.503    |
| AST (U/l)                      | 271 (±538)               | 722 (±602)           | 0.012    |
| ALP (U/l)                      | 463 (±508)               | 263 (±150)           | 0.084    |
| IgG (g/dL)                     | 21.0 (±12.0)             | 20.8 (±11.5)         | 0.990    |
| IgM (g/dL)                     | 2.47 (±1.44)             | 1.42 (±0.76)         | 0.002    |
| ANA or SMA (titre ≥1:40)       | 15                       | 12                   | 0.386    |
| AMA (titre ≥1:40)              | 2                       | 0                    | 0.480    |
| Alcohol intake <25g/day        | 23                      | 22                   | 0.600    |
| Other autoimmune disease       | 4                       | 8                    | 0.349    |
| Diabetes Mellitus              | 4                       | 5                    | 0.009    |
| Ulcerative Colitis             | 6                       | 2                    | 0.138    |
| IAHG score                     | 8.3 (±6.0)               | 12.6 (±4.9)          | 0.102    |

Values are mean (±standard deviation), or categorical frequency.
Statistical analysis

The Mann-Whitney test (for continuous, non-parametric data) was used to compare the cohort with the control group. The two-tailed Fisher’s exact test (employed because of the small sample size) was used to compare categorical variables. The Gamma test for concordance or discordance of ordinal variables was used to compare each patient group for degree of histological features. p-values <0.05 were considered significant. SPSS (Chicago, IL, USA. Edition 15.0, 2007) was used for statistical analysis.

**Table 2:**
Pathological features of pre-treatment liver biopsy at diagnosis of AIH in patients who subsequently developed cholestatic LFTs compared to AIH control group

| Characteristic (%) | Cholestatic group (n=24) | Control group (n=15) | p-value |
|-------------------|--------------------------|----------------------|---------|
| Granulomatous cholangitis (%) | 1 (10) | 0 (0) | 0.400 |
| Lymphocytic cholangitis (%) | 2 (20) | 1 (7) | 0.426 |
| Neutrophilic cholangitis (%) | 0 (0) | 2 (13) | 0.500 |
| Concentric portal fibrosis (%) | 0 (0) | 1 (7) | 1.000 |
| Ductopenia (%) | 3 (30) | 1 (7) | 0.287 |
| Substantial perportal ductular reaction (%) | 6 (60) | 6 (40) | 0.124 |
| Copper-associated protein deposition (%) | 5 (50) | 2 (13) | 0.132 |
| Cholestatic steatosis (%) | 2 (20) | 1 (7) | 0.543 |
| Canaliculitis (%) | 1 (10) | 5 (33) | 0.289 |
| Biliary changes (IAHG criteria) (%) | 4 (40) | 2 (13) | 0.175 |
| Predominant lymphoid/Mixed inflammatory hyperplasia (%) | 6 (60) | 9 (60) | 1.000 |
| Liver cell rosetting (%) | 2 (20) | 5 (33) | 0.659 |
| Severe interface hepatitis (%) | 2 (20) | 6 (40) | 0.232 |
| Confluent necrosis (%) | 2 (20) | 7 (47) | 0.439 |
| Moderate/severe spot necrosis (%) | 3 (30) | 8 (53) | 0.826 |
| Marked portal inflammation (%) | 1 (10) | 4 (27) | 0.493 |
| Modified Hikijima staging score (mean±SD) | 2.5 ± (2.2) | 1.3 ± (1.0) | 0.221 |

**RESULTS**

The clinical and laboratory characteristics from the time of diagnosis of the cholestatic group of AIH patients (n=24) and the matched control AIH group (n=25) are summarised in Table 1. The cholestatic group had a lower AST (p=0.012), higher IgM (p=0.002), and lower IAHG score (p=0.102) at presentation compared to the control group. The other parameters recorded were similar for both groups.

Only 10 of the 24 patients with cholestatic LFTs (including four of the 12 overlap cases), and 15 of the 25 patients in the control group, had an initial liver biopsy which was available for review. Therefore statistical evaluation of histology data was limited. Of the histological features assessed (Table 2), ductopenia, substantial perportal ductular reaction, copper-associated protein deposition, and overall ‘biliary changes’, as defined by IAHG criteria, occurred more frequently in the cholestatic group and hepatic features were more prominent in the control AIH group, but none of the changes reached statistical significance.

In our cohort, 12 (50%) of AIH patients with cholestatic LFTs had features of PSC on MRC. At the time of initiation of this study, eight cases of AIH had already been reclassified as AIH / PSC overlap syndrome. During the course of this study, four more patients with cholestatic LFTs were demonstrated to have cholangiographic features consistent with or suspicious of PSC.

Comparison of the AIH / PSC OLS group (defined by abnormal MRC), the cholestatic LFT group (with normal MRC), and the control AIH group, showed a similar duration of clinical follow up (mean 11.2 years, range 2-28 years). Rates of clinical remission, relapse, liver failure requiring transplantation, or death, were similar between each of these three groups.

**DISCUSSION**

This study showed that, of 24 patients who were identified from a cohort of 118 AIH patients by the development of cholestatic LFTs, one half (12/24) had features of PSC on MRC evaluation, indicating a diagnosis of AIH / PSC OLS. A retrospective comparison of this cholestatic group with a control population at the time of presentation, was performed in an attempt to identify important early predictive features for developing OLS. At time of original diagnosis of AIH, patients in the cholestatic group had lower transaminases, higher serum IgM levels and a greater incidence of ulcerative colitis. IAHG scores were lower than the control group. In our cohort, no other clinical or pathological differences between the two groups were statistically significant.

Many groups have studied patients with autoimmune liver disease. Abdaliamian et al. prospectively studied 79 patients with a clinical diagnosis of AIH. They found that 10% had definite or probable PSC on MRC. Predictors of PSC were younger age at diagnosis, elevated alkaline phophatase at diagnosis, elevated bilirubin at time of MRC, and greater lobular activity on initial liver biopsy. Gheorghe et al. studied 82 patients with AIH. Only eight of this group underwent ERCP (based on a cholestatic biochemical or histological profile), of which seven were positive for features of PSC. Therefore at least 7% of their AIH cohort had features of AIH / PSC OLS. Our finding that at least 12 (10%) of 118 AIH patients developed AIH / PSC OLS is consistent with these studies. The most comprehensive descriptive epidemiology of autoimmune liver disease prevalence and categorisation comes from Czaja et al., who retrospectively reviewed 225 patients with any autoimmune liver disease. Of the 225 patients, 18% were reclassified as having OLS. 14 of 26 patients with PSC (54%) were found to have features of AIH and PSC.

Four large studies have reviewed patients with cholangiographically-proven PSC for features of AIH (assessed by IAHG criteria). Kaya et al reported 1.4% of PSC cases had ‘definite’ AIH and 6% had ‘probable’ AIH. Floriani et al. found 17% with AIH, van Burren et al. (n=113) found 8% with ‘definite’ AIH, and Boberg et al. (n=114) found 2% with ‘definite’ and 33% with ‘probable’ AIH.

The pathogenesis, time of disease onset, and sequence of progression of AIH / PSC OLS is poorly understood. Retrospective analysis of the initial diagnosis is usually impossible because most patients do not have both cholangiography and liver biopsy performed at time of diagnosis of AIH. McNair et al. presented five cases of AIH / PSC OLS. Two had ‘pure’ AIH at diagnosis, which transformed into AIH / PSC OLS subsequently. Three had concurrent features of AIH and PSC at presentation. Abdou et al. reviewed 91 patients with AIH. Six patients (7%) subsequently developed cholangiographically-proven PSC. This included three patients with a previously normal cholangiogram, performed after the initial diagnosis of AIH.
a diagnosis of AIH (n=28) or PSC (n=27). All patients underwent biopsy and cholangiography at presentation. Of the 27 patients with PSC, 14 (52%) had ‘definite’ and 13 (48%) ‘probable’ AIH by IAHG scores. One patient with ‘pure’ AIH and normal cholangiography at presentation, subsequently developed cholangiographically-proven PSC. As discussed by these and other authors, it appears that some cases of ‘pure’ AIH, with no features to indicate AIH / PSC OLS at diagnosis originally, subsequently can transform into AIH / PSC OLS\(^2\).\

The main weaknesses of this study are the small number of patients and incomplete data. Clinical notes for baseline data at diagnosis were not always available due to the long duration of follow-up. Many cases did not have a liver biopsy performed and some liver biopsies were unavailable or uninterpretable. MRC scanning is clearly preferable to ERCP from a patient perspective, but may cause claustrophobia, which prevented MRC in one case. MRC has a sensitivity of 82 to 91% and specificity of 85 to 98%\(^2\)\(^4\)-\(^2\), when compared to the ‘gold standard’ ERCP for the diagnosis of PSC. The sensitivity of MRC has improved due to better availability and quality of MR scanning. ‘Small duct’ PSC (biochemical and histological features of PSC, but normal cholangiography) will not necessarily have been identified by our investigations. Angulo et al.\(^2\) identified 18 patients (5.8%) from their PSC cohort (n=309), with ‘small duct’ PSC. Only 25 AIH patients, out of our cohort of 118, underwent cholangiography. Therefore, the prevalence of AIH / PSC OLS may be even greater in our cohort.

This is the first study to examine whether an earlier diagnosis of AIH/PSC OLS could be made in patients with an initial clinical diagnosis of AIH. Our study reiterates the finding of other groups: a significant minority of patients diagnosed with AIH will eventually turn out to have AIH / PSC OLS. There are no clinical, biochemical, serological or histological findings which strongly predict this development. Therefore, we recommend that MRC should be performed in every case of AIH where there is an elevation of ALP and GGT, following a poor transaminase response to corticosteroids. In the event of a normal MRC, liver biopsy should be considered to look for small duct disease. The frequency with which MRC would be performed and whether MRC would reveal cases of AIH/PSC OLS in AIH patients with normal ALP and GGT remain to be determined.

The authors have no conflict of interest.

**REFERENCES**

1. Ben-Ari Z, Czaia AJ. Autoimmune hepatitis and its variant syndromes. *Gut*. 2001;49 (4):589-94.
2. Durazzo M, Premoli A, Fagonee S, Pellicano R. Overlap syndromes of autoimmune hepatitis. What is known so far. *Dig Dis Sci*. 2005;48 (3):423-30.
3. Czaia AJ. Natural history, clinical features and treatment of autoimmune hepatitis. *Semin Liver Dis.* 1984;4 (1):1-12.
4. Bokberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Sparkland A, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation on 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. *Hepatology*. 1996;23 (6):1369-76.
5. Rust C, Beuers U. Overlap syndromes among autoimmune liver diseases. *World J Gastroenterol*. 2008;14(21):3368-73.
6. Johnston PJ, McFarlane IG. Meeting report. International Autoimmune Hepatitis Group. *Hepatology*. 1993;18 (4):998-1005.
7. Alvarez F, Berg PA, Bianchi EB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol*. 1999;31 (5):929-38.
8. Czaia A, Carpenter HA. Validation of the scoring system for diagnosis of autoimmune hepatitis. *Dig Dis Sci*. 1996;41 (2):305-14.
9. McFarlane IG. Autoimmune hepatitis. Clinical manifestations and diagnostic criteria. *Can J Gastroenterol*. 2001;15 (2):107-113.
10. Gheorghe L, Iacob S, Gheorghe C, Iacob R, Simionov I, Vadan R, et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. *Eur J Gastroenterol Hepatol*. 2004;16 (6):585-592.
11. Abdulian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote J. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance Imaging. *Hepatology*. 2008;47 (3):949-57.
12. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. *J Hepatol*. 2000;33 (4):537-42.
13. van Burren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FJ. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. *J Hepatol*. 2000;33 (4):543-8.
14. Florenni A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, et al. Clinical course and outcome of autoimmune hepatitis / primary sclerosing cholangitis overlap syndrome. *Am J Gastroenterol*. 2005;100 (7):1516-22.
15. Czaia AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. *Hepatology*. 1998;28 (2):360-5.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Schuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*. 1994;19 (6):1513-20.
17. Czaia AJ, Carpenter HA. Autoimmune liver disease. In: Burt AD, Portmann BC, Ferrell LD, editors. MacSween’s Pathology of the Liver. 5th ed. Edinburgh: Churchill Livingstone; 2007. p. 493-516.
18. Knoedell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. *Hepatology*. 1981;1 (5):431-5.
19. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. *World J Gastroenterol*. 2008;14 (21):3350-9.
20. Vergani D, Miele-Vergani G. Aetio-pathogenesis of autoimmune hepatitis. *World J Gastroenterol*. 2008;14 (21):3306-12.
21. McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. *Am J Gastroenterol*. 1998;93 (5):777-84.
22. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential phenotype. *Hepatology*. 2002;36 (6):1393-9.
23. Gregorioti GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis / sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. *Hepatology*. 2001;33 (3):544-53.
24. Talwalkar JA, Angulo P, Johnson CD, Petersen BY, Lindor KD. Cost minimisation analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. *Hepatology*. 2004;40 (1):39-45.
25. Moff SL, Karmel IR, Eustace J, Lawler LP, Kantelevs S, Kalloo AN, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. *Gastrointest Endosc*. 2006;64 (2):219-23.
26. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long term follow-up study. *Hepatology*. 2002;35 (6):1494-1500.